The treatment, if approved, “will represent the first novel pharmacological approach to treating schizophrenia in several decades and provide a new treatment option for patients and their physicians.”
Karuna Therapeutics Reports Second Quarter 2023 Financial Results and Provides General Business Updates streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Announced positive topline data from the Phase 3 EMERGENT-3 trial of KarXT in schizophrenia in the first quarter of 2023
On track to submit New Drug Application for KarXT in schizophrenia with the. | May 4, 2023
KarXT (xanomeline-trospium) was found to significantly reduce symptoms of schizophrenia in adult patients, according to topline results from the phase 3 EMERGENT-3 trial.